DIPG
MCID: DFF039
MIFTS: 57

Diffuse Midline Glioma, H3 K27m-Mutant (DIPG)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Diffuse Midline Glioma, H3 K27m-Mutant

MalaCards integrated aliases for Diffuse Midline Glioma, H3 K27m-Mutant:

Name: Diffuse Midline Glioma, H3 K27m-Mutant 11 14
Diffuse Intrinsic Pontine Glioma 11 19 58 5 16 71 75
Dipg 19 58
Infiltrative Brainstem Glioma 19

Characteristics:


Prevelance:

Diffuse Intrinsic Pontine Glioma: <1/1000000 (Netherlands) 58

Age Of Onset:

Diffuse Intrinsic Pontine Glioma: All ages 58

Age Of Death:

Diffuse Intrinsic Pontine Glioma: any age 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:0080684
NCIt 49 C129309
Orphanet 58 ORPHA497188
UMLS 71 C2986658

Summaries for Diffuse Midline Glioma, H3 K27m-Mutant

Orphanet: 58 A rare glial tumor characterized by a highly aggressive, diffusely infiltrative pontine lesion generally occurring in children, affecting local nerve fiber tracts and spreading contiguously to involve adjacent structures, but also metastasizing within the central nervous system. Patients mostly present with a short history of symptoms, typically including the classic triad of multiple cranial neuropathies, long tract signs, and ataxia. Signs and symptoms of increased intracranial pressure may present due to obstructive hydrocephalus. Prognosis is poor and not related to histological grade.

MalaCards based summary: Diffuse Midline Glioma, H3 K27m-Mutant, also known as diffuse intrinsic pontine glioma, is related to glioblastoma and brain stem glioma. An important gene associated with Diffuse Midline Glioma, H3 K27m-Mutant is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are Gene expression (Transcription) and Metabolism of proteins. The drugs Prednisone and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and pons, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology: 11 A histone mutated tumor that is characterized by the presence of histone H3 K27M mutation located throughout the midline structures of the central nervous system.

GARD: 19 A neuroglial tumor that arises from the middle portion of the brain stem. It usually affects children and has a poor prognosis.

Wikipedia: 75 A diffuse intrinsic pontine glioma (DIPG) is a tumour located in the pons (middle) of the brain stem.... more...

Related Diseases for Diffuse Midline Glioma, H3 K27m-Mutant

Diseases related to Diffuse Midline Glioma, H3 K27m-Mutant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 glioblastoma 31.2 PDGFRA H3C4 H3C1 H3-3B H3-3A BRCA2
2 brain stem glioma 31.0 H3C6 H3C4 H3C3 H3C2 H3C12 H3C11
3 juvenile pilocytic astrocytoma 30.9 H3C6 H3C4 H3C3 H3-3B H3-3A
4 fibrillary astrocytoma 30.7 H3-3B H3-3A
5 nijmegen breakage syndrome 30.7 H2AC18 CHEK2 BRCA2
6 anaplastic astrocytoma 30.4 PDGFRA H3C6 H3C4 H3C3 H3C2 H3C11
7 brain stem astrocytic neoplasm 30.4 H3-3B ATRX
8 diffuse astrocytoma 30.3 PDGFRA H3C6 H3C4 H3C3 H3C2 H3C12
9 pilocytic astrocytoma 30.0 PDGFRA H3C8 H3C7 H3C6 H3C4 H3C3
10 low grade glioma 29.6 PDGFRA H3C8 H3C7 H3C6 H3C4 H3C3
11 brain cancer 11.0
12 glioma susceptibility 1 10.8
13 glioma 10.8
14 glial tumor 10.8
15 factor vii deficiency 10.6
16 brain tumor, childhood 10.5
17 hydrocephalus 10.5
18 mismatch repair cancer syndrome 1 10.4
19 neutropenia 10.4
20 central nervous system cancer 10.4
21 cranial nerve palsy 10.4
22 hereditary breast cancer 10.4 CHEK2 BRCA2
23 bone giant cell sarcoma 10.4 H3-3B H3-3A
24 fanconi anemia, complementation group n 10.4 BRIP1 BRCA2
25 tracheoesophageal fistula with or without esophageal atresia 10.4 BRIP1 BRCA2
26 periosteal osteogenic sarcoma 10.4 H3-3B H3-3A
27 malignant giant cell tumor 10.4 H3-3B H3-3A
28 breast-ovarian cancer, familial 1 10.4 BRIP1 BRCA2
29 ovarian cancer 1 10.4 BRIP1 BRCA2
30 telangiectatic osteogenic sarcoma 10.4 H3-3B H3-3A
31 autosomal recessive cerebellar ataxia 10.4 H2AC18 CHEK2 BRCA2
32 retinoblastoma 10.4
33 thrombocytopenia 10.4
34 bone giant cell tumor 10.4 H3-3B H3-3A H2AC18
35 chondroblastic osteosarcoma 10.4 H3-3B H3-3A
36 alpha-thalassemia/mental retardation syndrome, x-linked 10.4
37 high grade glioma 10.4
38 paraplegia 10.4
39 chondroblastoma 10.4 H3-3B H3-3A H2AC18
40 connective tissue benign neoplasm 10.4 H3-3B H3-3A H2AC18
41 ovarian carcinosarcoma 10.4 H2AC18 BRCA2
42 sporadic breast cancer 10.4 H2AC18 CHEK2 BRIP1 BRCA2
43 oculoectodermal syndrome 10.4 H3-3B H3-3A
44 adult brain stem glioma 10.3 H3-3B H3-3A ATRX
45 idh-wildtype anaplastic astrocytoma 10.3 H3-3B H3-3A ATRX
46 adult oligodendroglioma 10.3 H3-3B H3-3A ATRX
47 childhood oligodendroglioma 10.3 H3-3B H3-3A ATRX
48 gliomatosis cerebri 10.3 H3-3B H3-3A ATRX
49 dysembryoplastic neuroepithelial tumor 10.3 H3-3B H3-3A ATRX
50 seckel syndrome 10.3 H2AC18 CHEK2 BRIP1 BRCA2

Graphical network of the top 20 diseases related to Diffuse Midline Glioma, H3 K27m-Mutant:



Diseases related to Diffuse Midline Glioma, H3 K27m-Mutant

Symptoms & Phenotypes for Diffuse Midline Glioma, H3 K27m-Mutant

GenomeRNAi Phenotypes related to Diffuse Midline Glioma, H3 K27m-Mutant according to GeneCards Suite gene sharing:

25 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.04 CHEK2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.04 H3C10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.04 BRIP1 H3C1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.04 CHEK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.04 CHEK2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.04 ACVR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.04 H3C10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.04 CHEK2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.04 BRIP1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.04 CHEK2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.04 ACVR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.04 BRIP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.04 H3C10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-142 10.04 CHEK2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-160 10.04 ACVR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.04 H3C10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.04 H3C1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-193 10.04 H3C1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.04 BRIP1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.04 ACVR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.04 H3C1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-40 10.04 H3C1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.04 H3C10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.04 H3C1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.04 ACVR1 H3C1 CHEK2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.04 ACVR1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.04 BRIP1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.04 ACVR1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.04 H2AC18
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.04 ACVR1 CHEK2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.04 ACVR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.04 H3C10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.04 H2AC18

Drugs & Therapeutics for Diffuse Midline Glioma, H3 K27m-Mutant

Drugs for Diffuse Midline Glioma, H3 K27m-Mutant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
8
Palifosfamide Investigational Phase 3 31645-39-3 100427
9
Nimotuzumab Investigational Phase 3 780758-10-3
10 Dermatologic Agents Phase 3
11 glucocorticoids Phase 3
12 Antineoplastic Agents, Hormonal Phase 3
13 Folic Acid Antagonists Phase 3
14 Folate Phase 3
15 Calcium, Dietary Phase 3
16 Hormones Phase 3
17 Hormone Antagonists Phase 3
18 Vitamin B9 Phase 3
19 Anti-Inflammatory Agents Phase 3
20 Vitamin B Complex Phase 3
21 Neurotransmitter Agents Phase 3
22 Anticonvulsants Phase 3
23 Psychotropic Drugs Phase 3
24 Pharmaceutical Solutions Phase 3
25
Calcium Nutraceutical Phase 3 7440-70-2 271
26
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
27
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
28
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
29
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
30
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
31
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
32
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
33
Etoposide Approved Phase 2 33419-42-0 36462
34
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
35
Cemiplimab Approved, Investigational Phase 1, Phase 2 1801342-60-8
36
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
37
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
38
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
39
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
40
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
41
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
42
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
43
Eflornithine Approved, Withdrawn Phase 1, Phase 2 70052-12-9 3009
44
Nivolumab Approved Phase 1, Phase 2 946414-94-4
45
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605 16129706
46
Lutetium Lu 177 dotatate Approved, Investigational Phase 1, Phase 2 437608-50-9 76966897
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
48
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
49
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
50
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
2 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT05476939 Phase 3 Everolimus;ONC201
3 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
4 A Multicenter, Prospective, Open and Single Arm Clinical Study of Nimotuzumab Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children Recruiting NCT04532229 Phase 3 Nimotuzumab+CRT(concurrent IMRT and TMZ)
5 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Unknown status NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
6 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
7 An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy Completed NCT03566199 Phase 1, Phase 2 Panobinostat Nanoparticle Formulation MTX110;Convection-Enhanced Delivery (CED)
8 Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma Completed NCT00600054 Phase 2
9 Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children Completed NCT01777633 Phase 1, Phase 2
10 A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) Completed NCT01189266 Phase 1, Phase 2 Vorinostat
11 A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children With Diffuse Pontine Gliomas Completed NCT00036569 Phase 2
12 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Completed NCT00879437 Phase 2 Valproic acid;Bevacizumab
13 A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas Completed NCT02750891 Phase 1, Phase 2 DSP-7888
14 Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma Completed NCT01469247 Phase 1, Phase 2
15 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
16 A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression Recruiting NCT05009992 Phase 2 ONC201;Paxalisib
17 Phase IB Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AloCELYVIR (Mesenchymal Allogenic Cells + ICOVIR-5) in Children, Adolescent and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Relapse/Progression in Monotherapy Recruiting NCT04758533 Phase 1, Phase 2
18 A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Recruiting NCT05099003 Phase 1, Phase 2 Selinexor
19 A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma Recruiting NCT04250064 Phase 2 Bevacizumab Injection
20 A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma Recruiting NCT03690869 Phase 1, Phase 2 cemiplimab (monotherapy);cemiplimab (maintenance)
21 Adjuvant Dendritic Cell Immunotherapy Complementing Conventional Therapy for Pediatric Patients With High-grade Glioma and Diffuse Intrinsic Pontine Glioma Recruiting NCT04911621 Phase 1, Phase 2
22 A Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination With Exablate 4000 Type-2 MR-Guided Focused Ultrasound in Subjects With Diffuse Intrinsic Pontine Glioma Recruiting NCT05123534 Phase 2
23 PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS Recruiting NCT03709680 Phase 2 Palbociclib;Temozolomide;Irinotecan;Topotecan;Cyclophosphamide
24 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Recruiting NCT04049669 Phase 2 Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
25 Phase 2 Randomized Study of RT and Reirradiation at Relapse vs Multiple Elective RT Courses With Same Concomitant CT for Newly Diagnosed Recruiting NCT03620032 Phase 2 Nimotuzumab;Vinorelbine
26 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
27 A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer Recruiting NCT05500508 Phase 1, Phase 2 AMXT1501;DFMO
28 Stereotactic Biopsy Split-Course Radiation Therapy - Diffuse Midline Glioma (SPORT-DMG) Recruiting NCT05077735 Phase 2
29 H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC With and Without PD-1 Inhibition Using Nivolumab for the Treatment of Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Gliomas Active, not recruiting NCT02960230 Phase 1, Phase 2 Nivolumab
30 A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Active, not recruiting NCT04870944 Phase 1, Phase 2 FACT Complex-targeting Curaxin CBL0137
31 Phase I/II Study of Lutathera in Pediatric and Young Adult Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Express Somatostatin Type2A Receptors and Demonstrate Uptake on DOTATATE PET Not yet recruiting NCT05278208 Phase 1, Phase 2 LUTATHERA® (Lutetium Lu 177 dotatate)
32 Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma Not yet recruiting NCT05096481 Phase 2 Temozolomide
33 A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG) Suspended NCT02742883 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
34 An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) Terminated NCT02758366 Phase 2 Doxorubicin
35 A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma Terminated NCT01836549 Phase 2 imetelstat sodium
36 A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Terminated NCT02607124 Phase 1, Phase 2 Ribociclib
37 A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects Terminated NCT03330197 Phase 1, Phase 2 Oral Veledimex - Arm 1 (Pediatric Brain Tumor);Oral Veledimex - Arm 2 (DIPG)
38 Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Terminated NCT01182350 Phase 2 Bevacizumab;Erlotinib;Temozolomide
39 Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Terminated NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
40 Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group - Terminated NCT01517776 Phase 2 Cilengitide;Temozolomide
41 A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation Withdrawn NCT03632317 Phase 2 Panobinostat;Everolimus
42 Phase Ib Clinical Trial on the Safety of Immunotherapy With Autologous Dendritic Cells Primed With Lysate Allogeneic Tumor Lines in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Unknown status NCT02840123 Phase 1
43 Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Unknown status NCT03178032 Phase 1
44 Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma Completed NCT01393912 Phase 1 Crenolanib
45 A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors Completed NCT03387020 Phase 1 Everolimus;Ribociclib
46 A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma Completed NCT03086616 Phase 1 Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
47 Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study Completed NCT01165333 Phase 1 Cilengitide dose escalation;Cilengitide
48 Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma Completed NCT00996723 Phase 1 vandetanib and dasatinib
49 Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). Completed NCT01688401 Phase 1 Melphalan hydrochloride
50 A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas Completed NCT01222754 Phase 1 Lenalidomide

Search NIH Clinical Center for Diffuse Midline Glioma, H3 K27m-Mutant

Genetic Tests for Diffuse Midline Glioma, H3 K27m-Mutant

Anatomical Context for Diffuse Midline Glioma, H3 K27m-Mutant

Organs/tissues related to Diffuse Midline Glioma, H3 K27m-Mutant:

MalaCards : Spinal Cord, Brain, Pons, T Cells, Eye, Hypothalamus, Pineal

Publications for Diffuse Midline Glioma, H3 K27m-Mutant

Articles related to Diffuse Midline Glioma, H3 K27m-Mutant:

(show top 50) (show all 761)
# Title Authors PMID Year
1
Comparison of Sonication Patterns and Microbubble Administration Strategies for Focused Ultrasound-Mediated Large-Volume Drug Delivery. 62
35476579 2022
2
5-ALA fluorescence in randomly selected pediatric brain tumors assessed by spectroscopy and surgical microscope. 62
36242636 2022
3
Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. 62
36259971 2022
4
H3F3A K27M Mutation Promotes the Infiltrative Growth of High-Grade Glioma in Adults by Activating β-Catenin/USP1 Signaling. 62
36230759 2022
5
Biopsy of paediatric brainstem intrinsic tumours: Experience from a Singapore Children's Hospital. 62
36228504 2022
6
Tasadenoturev active in DIPG. 62
35869159 2022
7
A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy. 62
36077842 2022
8
DIPG- Very Long-Term Survivors - are There Factors Which May Predict a Better Outcome? 62
36162411 2022
9
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. 62
35148393 2022
10
No wrong decisions in an all-wrong situation. A qualitative study on the lived experiences of families of children with diffuse intrinsic pontine glioma. 62
35652529 2022
11
Oncolytic Viral Therapy Is Feasible in Diffuse Intrinsic Pontine Glioma. 62
35801932 2022
12
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. 62
35481923 2022
13
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5. 62
35915262 2022
14
Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma. 62
35933568 2022
15
Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. 62
35852795 2022
16
PRC2-indepdendent actions of H3.3K27M in embryonic stem cell differentiation. 62
36156096 2022
17
Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting. 62
36003055 2022
18
Leptomeningeal and subependymal seeding of diffuse intrinsic pontine glioma: a case report. 62
35290487 2022
19
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. 62
36145510 2022
20
Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. 62
35716669 2022
21
Enhancing GD2 CAR T-cell therapy with IGF-1R blockade: Are DIPG CAR T cells ready for combinatorial therapy? 62
35323961 2022
22
Treatment Limitations for Pediatric Diffuse Intrinsic Pontine Gliomas in a Middle-Income Country. 62
35945995 2022
23
The Novel Monooxygenase Gene dipD in the dip Gene Cluster of Alcaligenes faecalis JQ135 Is Essential for the Initial Catabolism of Dipicolinic Acid. 62
35766505 2022
24
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. 62
34964902 2022
25
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2. 62
35859885 2022
26
Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. 62
35585670 2022
27
A practical solution to estimate the sample size required for clinical prediction models generated from observational research on data. 62
35641659 2022
28
Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. 62
35768942 2022
29
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. 62
35767439 2022
30
Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases. 62
35416795 2022
31
Hypofractionated Radiation Therapy For Diffuse Intrinsic Pontine Glioma: A Noninferiority Randomized Study Including 253 Children. 62
35150788 2022
32
A homogeneous treatment for non-DIPG diffuse midline glioma. 62
35708347 2022
33
Coping with Diffuse Intrinsic Pontine Glioma in Children - Findings from an Interview Study on Bereaved Parents. 62
35654395 2022
34
Characteristics of Children ≤36 Months of Age with Diffuse Intrinsic Pontine Glioma (DIPG): A Report from the International DIPG Registry. 62
35552452 2022
35
Quantitative Sodium (23Na) MRI in Pediatric Gliomas: Initial Experience. 62
35626378 2022
36
Palliative and end-of-life symptoms management for children with diffuse intrinsic pontine glioma. 62
35193393 2022
37
Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG. 62
35590427 2022
38
Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials. 62
35629262 2022
39
Mechanistic Insights into Deregulated TGF-β Family Signalling in Human Disease. 62
35554739 2022
40
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. 62
34668975 2022
41
The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential. 62
35637482 2022
42
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. 62
35393952 2022
43
Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors. 62
35645204 2022
44
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. 62
34347089 2022
45
Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients. 62
35395636 2022
46
Extraneural Metastases of Diffuse Midline Glioma, H3 K27M-Mutant at Diagnosis: Case Report, Review of the Literature, and Identifying Targetable Alterations. 62
33974582 2022
47
Focused Ultrasound for Pediatric Diseases. 62
35229123 2022
48
The effects of glycols on molecular mobility, structure, and permeability in stratum corneum. 62
35150813 2022
49
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. 62
34737188 2022
50
Diffuse intrinsic pontine gliomas in adults: A retrospective study. 62
35532623 2022

Variations for Diffuse Midline Glioma, H3 K27m-Mutant

ClinVar genetic disease variations for Diffuse Midline Glioma, H3 K27m-Mutant:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ACVR1 NM_001111067.4(ACVR1):c.983G>T (p.Gly328Val) SNV Other
376363 rs387906589 GRCh37: 2:158622516-158622516
GRCh38: 2:157766004-157766004
2 BRCA2 NM_000059.4(BRCA2):c.4478_4481del (p.Glu1493fs) MICROSAT Pathogenic
51653 rs80359454 GRCh37: 13:32912965-32912968
GRCh38: 13:32338828-32338831
3 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs) DEL Pathogenic
128042 rs555607708 GRCh37: 22:29091857-29091857
GRCh38: 22:28695869-28695869
4 BRIP1 NM_032043.3(BRIP1):c.1045G>C (p.Ala349Pro) SNV Likely Pathogenic
30535 rs149364097 GRCh37: 17:59878709-59878709
GRCh38: 17:61801348-61801348
5 NF1 NM_001042492.3(NF1):c.1888G>A (p.Val630Ile) SNV Uncertain Significance
220148 rs751795238 GRCh37: 17:29552155-29552155
GRCh38: 17:31225137-31225137

Cosmic variations for Diffuse Midline Glioma, H3 K27m-Mutant:

8 (show top 50) (show all 20001)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM85192834 ZW10 central nervous system,brain,glioma,NS c.2140C>T p.P714S 11:113736699-113736699 8
2 COSM86922763 ZSWIM4 central nervous system,brain,glioma,NS c.266C>T p.P89L 19:13799832-13799832 8
3 COSM88263742 ZRSR2 central nervous system,brain,glioma,NS c.340C>T p.Q114* 23:15804138-15804138 8
4 COSM88261602 ZRSR2 central nervous system,brain,glioma,NS c.961C>T p.P321S 23:15822754-15822754 8
5 COSM88263021 ZRSR2 central nervous system,brain,glioma,NS c.260G>A p.R87K 23:15803744-15803744 8
6 COSM88261596 ZRSR2 central nervous system,brain,glioma,NS c.271G>A p.E91K 23:15803755-15803755 8
7 COSM88262556 ZRSR2 central nervous system,brain,glioma,NS c.220G>A p.E74K 23:15803704-15803704 8
8 COSM87830624 ZPLD1 central nervous system,brain,glioma,NS c.393A>T p.G131= 3:102456210-102456210 8
9 COSM119316158 ZPLD1 central nervous system,brain,glioma,NS c.345A>T p.G115= 3:102456210-102456210 8
10 COSM116178212 ZPLD1 central nervous system,brain,glioma,NS c.345A>T p.G115= 3:102456210-102456210 8
11 COSM106156998 ZNF697 central nervous system,brain,glioma,NS c.1550G>A p.G517D 1:119622793-119622793 8
12 COSM93171584 ZNF687 central nervous system,brain,glioma,NS c.3651C>T p.T1217= 1:151291146-151291146 8
13 COSM93173649 ZNF687 central nervous system,brain,glioma,NS c.2044T>A p.C682S 1:151288335-151288335 8
14 COSM93173639 ZNF687 central nervous system,brain,glioma,NS c.2043G>C p.Q681H 1:151288334-151288334 8
15 COSM92762364 ZNF507 central nervous system,brain,glioma,NS c.1517G>C p.R506T 19:32354347-32354347 8
16 COSM91851905 ZNF507 central nervous system,brain,glioma,NS c.1517G>C p.R506T 19:32354347-32354347 8
17 COSM130988554 ZNF507 central nervous system,brain,glioma,NS c.1517G>C p.R506T 19:32354347-32354347 8
18 COSM141250987 ZNF473 central nervous system,brain,glioma,NS c.42C>T p.D14= 19:50039193-50039193 8
19 COSM84172269 ZNF473 central nervous system,brain,glioma,NS c.42C>T p.D14= 19:50039193-50039193 8
20 COSM141790125 ZNF473 central nervous system,brain,glioma,NS c.42C>T p.D14= 19:50039193-50039193 8
21 COSM99924035 ZNF473 central nervous system,brain,glioma,NS c.42C>T p.D14= 19:50039193-50039193 8
22 COSM111538647 ZNF473 central nervous system,brain,glioma,NS c.6C>T p.D2= 19:50039193-50039193 8
23 COSM84507966 ZNF276 central nervous system,brain,glioma,NS c.*664G>A p.? 16:89738910-89738910 8
24 COSM102909520 ZMYND8 central nervous system,brain,glioma,NS c.2116G>A p.D706N 20:47246116-47246116 8
25 COSM116582422 ZMYND8 central nervous system,brain,glioma,NS c.2176G>A p.D726N 20:47246116-47246116 8
26 COSM92864918 ZMYND8 central nervous system,brain,glioma,NS c.2102T>G p.V701G 20:47246130-47246130 8
27 COSM111370233 ZMYND8 central nervous system,brain,glioma,NS c.2116G>A p.D706N 20:47246116-47246116 8
28 COSM91410147 ZMYND8 central nervous system,brain,glioma,NS c.2116G>A p.D706N 20:47246116-47246116 8
29 COSM97055096 ZMYND8 central nervous system,brain,glioma,NS c.1913T>G p.V638G 20:47246130-47246130 8
30 COSM112970642 ZMYND8 central nervous system,brain,glioma,NS c.2176G>A p.D726N 20:47246116-47246116 8
31 COSM92871777 ZMYND8 central nervous system,brain,glioma,NS c.2116G>A p.D706N 20:47246116-47246116 8
32 COSM85475347 ZMYND8 central nervous system,brain,glioma,NS c.2102T>G p.V701G 20:47246130-47246130 8
33 COSM143801239 ZMYND8 central nervous system,brain,glioma,NS c.2041G>A p.D681N 20:47246116-47246116 8
34 COSM114834078 ZMYND8 central nervous system,brain,glioma,NS c.2087T>G p.V696G 20:47246130-47246130 8
35 COSM114839982 ZMYND8 central nervous system,brain,glioma,NS c.2101G>A p.D701N 20:47246116-47246116 8
36 COSM91535436 ZMYND8 central nervous system,brain,glioma,NS c.2176G>A p.D726N 20:47246116-47246116 8
37 COSM91528627 ZMYND8 central nervous system,brain,glioma,NS c.2162T>G p.V721G 20:47246130-47246130 8
38 COSM133275210 ZMYND8 central nervous system,brain,glioma,NS c.1960G>A p.D654N 20:47246116-47246116 8
39 COSM143618110 ZMYND8 central nervous system,brain,glioma,NS c.2116G>A p.D706N 20:47246116-47246116 8
40 COSM111362863 ZMYND8 central nervous system,brain,glioma,NS c.2102T>G p.V701G 20:47246130-47246130 8
41 COSM91401933 ZMYND8 central nervous system,brain,glioma,NS c.2102T>G p.V701G 20:47246130-47246130 8
42 COSM130874736 ZMYND8 central nervous system,brain,glioma,NS c.2197G>A p.D733N 20:47246116-47246116 8
43 COSM116576154 ZMYND8 central nervous system,brain,glioma,NS c.2162T>G p.V721G 20:47246130-47246130 8
44 COSM143862983 ZMYND8 central nervous system,brain,glioma,NS c.2101G>A p.D701N 20:47246116-47246116 8
45 COSM143796197 ZMYND8 central nervous system,brain,glioma,NS c.2027T>G p.V676G 20:47246130-47246130 8
46 COSM102902986 ZMYND8 central nervous system,brain,glioma,NS c.2102T>G p.V701G 20:47246130-47246130 8
47 COSM133265728 ZMYND8 central nervous system,brain,glioma,NS c.1946T>G p.V649G 20:47246130-47246130 8
48 COSM85483642 ZMYND8 central nervous system,brain,glioma,NS c.2116G>A p.D706N 20:47246116-47246116 8
49 COSM112964306 ZMYND8 central nervous system,brain,glioma,NS c.2162T>G p.V721G 20:47246130-47246130 8
50 COSM143856741 ZMYND8 central nervous system,brain,glioma,NS c.2087T>G p.V696G 20:47246130-47246130 8

Expression for Diffuse Midline Glioma, H3 K27m-Mutant

Search GEO for disease gene expression data for Diffuse Midline Glioma, H3 K27m-Mutant.

Pathways for Diffuse Midline Glioma, H3 K27m-Mutant

Pathways related to Diffuse Midline Glioma, H3 K27m-Mutant according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 BRIP1 CHEK2 H2AC18 H3-3A H3-3B H3C1
2
Show member pathways
14 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
3
Show member pathways
13.95 PDGFRA H3C8 H3C7 H3C6 H3C4 H3C3
4
Show member pathways
13.94 ACVR1 CHEK2 H3-3A H3-3B H3C1 H3C10
5
Show member pathways
13.92 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
6
Show member pathways
13.92 ATRX BRCA2 BRIP1 H2AC18 H3-3A H3-3B
7 13.89 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
8
Show member pathways
13.87 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
9
Show member pathways
13.81 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
10
Show member pathways
13.79 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
11
Show member pathways
13.69 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12
12
Show member pathways
13.67 PDGFRA H3C8 H3C7 H3C6 H3C4 H3C3
13
Show member pathways
13.62 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
14
Show member pathways
13.62 PDGFRA H3C8 H3C7 H3C6 H3C4 H3C3
15
Show member pathways
13.61 ATRX BRCA2 BRIP1 CHEK2 H2AC18 H3-3A
16
Show member pathways
13.44 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
17
Show member pathways
13.43 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
18
Show member pathways
13.29 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
19
Show member pathways
13.25 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12
20
Show member pathways
13.18 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
21
Show member pathways
13.17 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
22
Show member pathways
13.15 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
23
Show member pathways
12.97 H3C6 H3C7 H3C8 H2AC18 H3-3A H3-3B
24
Show member pathways
12.96 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
25
Show member pathways
12.94 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
26
Show member pathways
12.91 BRCA2 H2AC18 H3-3A H3-3B H3C1 H3C10
27
Show member pathways
12.89 H2AC18 H3C1 H3C10 H3C11 H3C12 H3C2
28
Show member pathways
12.72 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
29 12.44 H3C1 CHEK2 BRIP1 BRCA2
30
Show member pathways
12.37 H3-3B H3-3A H2AC18 ATRX
31
Show member pathways
12.32 H3C10 H3C11 H3C12 H3C2 H3C3 H3C4
32 11.75 CHEK2 BRIP1 BRCA2
33 11.56 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12
34 11.54 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12
35 11.51 H3C1 H3C10 H3C11 H3C12 H3C2 H3C3
36 11.36 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12
37 11.3 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12

GO Terms for Diffuse Midline Glioma, H3 K27m-Mutant

Cellular components related to Diffuse Midline Glioma, H3 K27m-Mutant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.68 ATRX BRCA2 BRIP1 CHEK2 H2AC18 H3-3A
2 nucleoplasm GO:0005654 10.55 ATRX BRCA2 BRIP1 CHEK2 H3-3A H3-3B
3 extracellular region GO:0005576 10.54 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
4 extracellular exosome GO:0070062 10.48 H2AC18 H3-3A H3-3B H3C1 H3C10 H3C11
5 protein-containing complex GO:0032991 10.3 BRCA2 H3-3A H3-3B H3C1 H3C10 H3C11
6 chromosome, telomeric region GO:0000781 10.13 ATRX BRCA2 CHEK2 H3-3A H3-3B
7 chromatin GO:0000785 10.07 H3-3A H3-3B H3-7 H3C1 H3C10 H3C11
8 chromosome GO:0005694 9.86 ATRX BRCA2 H2AC18 H3-3A H3-3B H3-7
9 nucleosome GO:0000786 9.77 H2AC18 H3-3A H3-3B H3-7 H3C1 H3C10

Biological processes related to Diffuse Midline Glioma, H3 K27m-Mutant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleosome assembly GO:0006334 10.27 ATRX H3-3A H3-3B H3C1 H3C10 H3C11
2 telomere organization GO:0032200 10.03 H3-3A H3-3B H3C1 H3C10 H3C11 H3C12
3 epigenetic regulation of gene expression GO:0040029 9.62 H3C1 H3C10 H3C11 H3C12 H3C2 H3C3

Molecular functions related to Diffuse Midline Glioma, H3 K27m-Mutant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.33 ATRX BRCA2 BRIP1 H2AC18 H3-3A H3-3B
2 cadherin binding GO:0045296 10.3 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
3 structural constituent of chromatin GO:0030527 10.1 H3C8 H3C7 H3C6 H3C4 H3C3 H3C2
4 protein heterodimerization activity GO:0046982 9.77 H2AC18 H3-3A H3-3B H3-7 H3C1 H3C10

Sources for Diffuse Midline Glioma, H3 K27m-Mutant

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....